“Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues.”, J Infect Dis, vol. 202, no. 11, pp. 1649-58, 2010.
, “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older.”, Vaccine, vol. S0264-410X, no. 20, pp. 31504-31508, 2021.
, “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
, “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
, “Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.”, J Infect Dis, vol. 211, no. 6, pp. 870-8, 2015.
, “Norovirus vaccine against experimental human Norwalk Virus illness.”, N Engl J Med, vol. 365, no. 23, pp. 2178-87, 2011.
, “A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.”, J Infect Dis, vol. 210, no. 11, pp. 1763-71, 2014.
, “Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.”, Vaccine, vol. 30, no. 28, pp. 4240-8, 2012.
, “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.”, J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
, “Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax.”, Clin Vaccine Immunol, vol. 23, no. 12, pp. 918-925, 2016.
, “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
, ,
“Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
,